RCS - Q’Apel Medical, Inc. - Q’Apel’s Walrus Catheter Granted CE Mark Under MDR

General Motors CoAnnouncement

28/03/2023 14:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230328:nRSb2155Ua&default-theme=true

RNS Number : 2155U  Q’Apel Medical, Inc.  28 March 2023

Q'Apel Medical Inc. Granted CE Mark Under MDR for Their Walrus Balloon Guide
Catheter

FREMONT, CA / ACCESSWIRE / March 28, 2023 / Q'Apel
(https://pr.report/x1zwWJDy)  Medical Inc. was granted the CE Mark under MDR
for Walrus, their U.S. market-leading Balloon Guide Catheter (BGC) utilized in
treating patients suffering an acute ischemic stroke. The Walrus BGC has been
utilized by Neuro Interventional physicians since 2019 and has successfully
treated over 20,000 patients in the United States.

The Walrus BGC is a unique development in the field of Mechanical Thrombectomy
procedures. It provides physicians with not only the known benefits of BGC use
clinically, but unique to Walrus, superior ease of use in preparation in these
urgent procedures. Importantly, Walrus enables the physicians to navigate the
catheter into a more distal location easily and safely compared to other
systems, which is associated with improved patient outcomes from stroke.

"The anticipation of Walrus in our international markets has been enormous,
and we look forward to the same performance and loyalty around Walrus we have
been fortunate to experience in the United States," said King Nelson, Q'Apel
Medical's CEO.

"We are thrilled to be entering the EU and other international markets with
Walrus and providing more physicians in more countries the unparalleled
performance of our flagship catheter. This CE Mark certification represents a
significant growth milestone for Q'Apel Medical providing access to new
markets," commented Jodie Fam, Chief Marketing Officer & GM International.

About Q'Apel Medical

Q'Apel Medical designs highly innovative technologies for neurovascular
interventions and unmet clinical needs. Q'Apel's portfolio comprises three
products, the Walrus Balloon Catheter System, the Wahoo Hybrid Access System
and Armadillo Radial Access System. Before Walrus came along, balloon-based
variable stiffness catheters brought all manner of technological constraints.
Not anymore. By blending flow control, trackability, support, and access into
one revolutionary solution, Walrus offers truly unmatched functionality. The
Wahoo Hybrid Access System and Armadillo Radial Access System are dual-mode
catheters and part of the SelectFlex™ Family of Neurovascular Catheters.
These devices feature two distinct operational modes, allowing physicians to
easily switch modes at any point during a clinical case and reducing the need
for multiple catheters in challenging procedures.

Media Contact: Jodie Fam

415 244 9885

+44 7500702108

jfam@qapelmedical.com (https://pr.report/TC3HBuWa)
info@qapelmedical.com (https://pr.report/y26lcXYr)
www.qapelmedical.com (https://pr.report/7xETfUFu)

Contact Information

Jodie Fam

Chief Marketing Officer & GM International
jfam@qapelmedical.com (mailto:jfam@qapelmedical.com)

4152449885

SOURCE: Q'Apel Medical Inc.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAJIMRTMTMTBFJ